 |
|
|
| |
Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with
Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Poordad F,1 Schiff ER,2 Vierling JM,3 Landis C,4 Fontana RJ,5 Yang R,6 McPhee F,7 Hughes EA,6 Noviello S,6 Swenson ES7
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA; 3Baylor College of Medicine, Houston, TX, USA; 4University of Washington School of Medicine, Seattle, WA, USA; 5University of Michigan Medical Center, Ann Arbor, MI, USA; 6Bristol-Myers Squibb, Princeton, NJ, USA; 7Bristol-Myers Squibb, Wallingford, CT, USA
EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/23/15)
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/15/15)
Hepatology 2015
APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)
|
| |
|
|
|
|
|
